Cargando…

DDRE-33. MELATONIN AS A MASTER METABOLIC SWITCH FOR GLIOBLASTOMA

Glioblastoma (GBM) is the most common form of malignant primary brain cancer in adults with a median survival of only 15 months. Therefore, new therapies to suppress malignant brain cancer are needed. Brain Tumor Initiating Cells (BTICs) are a GBM subpopulation of cells with a highly glycolytic prof...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fernandez-Gil, Beatriz Irene, Vazquez-Ramos, Carla, Bechtle, Alexandra, Suarez-Meade, Paola, Qosja, Neda, Schiapparelli, Paula, Sarabia-Estrada, Rachel, Escames, Germaine, Quinones-Hinojosa, Alfredo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Supplement Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7992251/ http://dx.doi.org/10.1093/noajnl/vdab024.055

Ejemplares similares

Melatonin Treatment Triggers Metabolic and Intracellular pH Imbalance in Glioblastoma
por: Fernandez-Gil, Beatriz I., et al.
Publicado: (2022)

BSCI-27. MELATONIN REDUCES MALIGNANCY OF BREAST CANCER BRAIN METASTATIC CELLS
por: Gil, Beatriz Fernandez, et al.
Publicado: (2019)

DDRE-11. TARGETING FATTY ACID BIOSYNTHESIS IN GLIOBLASTOMA
por: Eyme, Katharina M, et al.
Publicado: (2021)

DDRE-15. THE EVOLUTIONARY ENIGMA OF FATTY ACID DESATURATION IN GLIOBLASTOMA
por: Oatman, Nicole, et al.
Publicado: (2021)

DDRE-24. TARGETING PURINE METABOLISM TO OVERCOME GLIOBLASTOMA THERAPY RESISTANCE
por: Zhou, Weihua, et al.
Publicado: (2021)

DDRE-13. INHIBITION OF EXTRACELLULAR CARBONIC ANHYDRASES INHIBITS GLIOBLASTOMA CELL INVASION
por: Proescholdt, Martin, et al.
Publicado: (2021)

DDRE-14. DE-NOVO PURINE BIOSYNTHESIS IS A MAJOR DRIVER OF CHEMORESISTANCE IN GLIOBLASTOMA
por: Ahmed, Atique
Publicado: (2021)

DDRE-21. THE FUNCTION OF MITOCHONDRIAL OSMR IN GLIOMA STEM CELL RESPIRATION AND GLIOBLASTOMA PATHOGENESIS
por: Jahani-Asl, Arezu, et al.
Publicado: (2021)

DDRE-28. MECHANISTIC AND THERAPEUTIC LINKS BETWEEN PURINE BIOSYNTHESIS AND DNA DAMAGE IN GLIOBLASTOMA
por: Scott, Andrew, et al.
Publicado: (2021)

DDRE-34. TARGETING RESISTANCE IN MEDULLOBLASTOMA
por: Chang, Simone, et al.
Publicado: (2021)

DDRE-16. CYSTEINE IS AN ESSENTIAL AMINO ACID IN GLIOMAS
por: Ruiz-Rodado, Victor, et al.
Publicado: (2021)

DDRE-09. THERAPEUTIC TARGETING OF PURINE METABOLISM IN DIPG
por: Mersich, Ian, et al.
Publicado: (2021)

DDRE-22. TARGETING SERINE SYNTHESIS IN BRAIN METASTASIS
por: Ngo, Bryan, et al.
Publicado: (2021)

DDRE-06. REGULATION OF TUMOR MICROENVIRONMENT VIA ENDOTHELIAL-TO-MESENCHYMAL TRANSITION BLOCKADE IN GLIOBLASTOMA-ASSOCIATED BRAIN ENDOTHELIAL CELLS
por: Marin’ Ramos, Nagore I, et al.
Publicado: (2021)

DDRE-26. THE IMMUNO-METABOLIC ENZYME FASN PREVENTS CANCER-CELL INTRINSIC TYPE I INTERFERON RESPONSES IN GLIOBLASTOMA
por: De Martino, Mara, et al.
Publicado: (2021)

DDRE-05. STEAROYL COA DESATURASE IS ESSENTIAL FOR REGULATION OF ENDOPLASMIC RETICULUM HOMEOSTASIS AND TUMOR GROWTH IN GLIOBLASTOMA CANCER STEM CELLS
por: Park, David, et al.
Publicado: (2021)

DDRE-18. THE MITOCHONDRIAL PYRUVATE CARRIER—A METABOLIC TARGET OF MALIGNANT GLIOMA
por: Tiburcio, Patricia, et al.
Publicado: (2021)

DDRE-07. FATTY ACID SYNTHESIS IS REQUIRED FOR BREAST CANCER BRAIN METASTASIS
por: Ferraro, Gino, et al.
Publicado: (2021)

DDRE-10. METABOLIC TARGETING OF HUMAN GLIOBLASTOMA USING 5-AMINOLEVULINIC ACID (ALA)-MEDIATED SONODYNAMIC THERAPY: A FIRST-IN-HUMAN STUDY
por: Marcus, Stuart, et al.
Publicado: (2021)

DDRE-04. THE COMBINED TREATMENT OF L-ASPARAGINASE AND 6-DIAZO-5-OXO-L-NORLEUCINE INHIBIT THE PROLIFERATION OF TEMOZOLOMIDE-SENSITIVE OR RESISTANT GLIOBLASTOMA CELLS
por: Ohba, Shigeo, et al.
Publicado: (2021)

DDRE-19. PHASE 0/I TRIAL OF MYCOPHENOLATE MOFETIL COMBINED WITH RADIATION TO OVERCOME GLIOBLASTOMA TREATMENT RESISTANCE BY TARGETING DE-NOVO PURINE METABOLISM
por: Umemura, Yoshie, et al.
Publicado: (2021)

DDRE-30. THERAPEUTIC TARGETING OF DISRUPTED METABOLIC STATE IN DIFFUSE INTRINSIC PONTINE GLIOMA
por: Mbah, Nneka, et al.
Publicado: (2021)

DDRE-32. THERAPEUTIC TARGETING OF A NOVEL METABOLIC ADDICTION IN DIFFUSE MIDLINE GLIOMA
por: Pal, Sharmistha, et al.
Publicado: (2021)

DDRE-20. TARGETING SPHINGOLIPID PATHWAY REVEALS VULNERABILITY IN IDH1(MUT) GLIOMA
por: Dowdy, Tyrone, et al.
Publicado: (2021)

DDRE-12. HETEROGENOUS RESPONSE OF IDH-MUTANT AND IDH-WT GLIOMA TO NAMPT INHIBITION
por: Rahman, Masum, et al.
Publicado: (2021)

DDRE-31. FEASIBILITY AND BIOLOGIC ACTIVITY OF A KETOGENIC / INTERMITTENT FASTING DIET IN GLIOMA PATIENTS
por: Schreck, Karisa, et al.
Publicado: (2021)

DDRE-29. DE NOVO PYRIMIDINE SYNTHESIS IS A TARGETABLE VULNERABILITY IN IDH-MUTANT GLIOMA
por: Shi, Diana D, et al.
Publicado: (2021)

DDRE-08. NRF2/GLUTATHIONE METABOLISM AS A NOVEL THERAPEUTIC TARGET FOR IDH1-MUTATED GLIOMA
por: Liu, Yang, et al.
Publicado: (2021)

DDRE-02. SMOOTHENED-ACTIVATING LIPIDS DRIVE RESISTANCE TO CDK4/6 INHIBITION IN HEDGEHOG-ASSOCIATED MEDULLOBLASTOMA
por: Daggubati, Vikas, et al.
Publicado: (2021)

DDRE-27. IDH MUTATED GLIOMAS PROMOTE EPILEPTOGENESIS VIA D-2-HYDROXYGLUTARATE DEPENDENT MTOR HYPERACTIVATION
por: Mortazavi, Armin, et al.
Publicado: (2021)

DDRE-03. IDH1-MUTANT GBM CELLS ARE HIGHLY SENSITIVE TO COMBINATION OF KDM6A/B AND HDAC INHIBITORS
por: Kayabölen, Alişan, et al.
Publicado: (2021)

DDRE-01. METABOLIC PLASTICITY AND HETEROGENEITY IN IDH1MUT CELL LINES PRODUCES RESISTANCE TO GLUTAMINASE INHIBITION BY CB839
por: Larion, Mioara, et al.
Publicado: (2021)

DDRE-25. INVESTIGATING MITOCHONDRIAL SLC25A TRANSPORTERS INVOLVED IN SUPPORTING BRAIN TUMOUR METABOLISM AND SURVIVAL UNDER HYPOXIC CONDITIONS
por: Eales, Katherine, et al.
Publicado: (2021)

DDRE-17. A PHASE I CLINICAL TRIAL OF DOSE-ESCALATED METABOLIC THERAPY COMBINED WITH CONCOMITANT RADIATION THERAPY IN HIGH-GRADE GLIOMA
por: Porper, Keren, et al.
Publicado: (2021)

SARS-CoV2 entry factors are expressed in primary human glioblastoma and recapitulated in cerebral organoid models
por: Suarez-Meade, Paola, et al.
Publicado: (2023)

DDRE-23. A COMPREHENSIVE CHARACTERIZATION OF THE GBM LIPIDOME REVEALS A MOLECULARLY-DEFINED SUB-GROUP WITH HEIGHTENED SENSITIVITY TO LIPID PEROXIDATION INDUCED CELL DEATH
por: Morrow, Danielle, et al.
Publicado: (2021)

Regulation of Glioblastoma Tumor-Propagating Cells by the Integrin Partner Tetraspanin CD151()()
por: Tilghman, Jessica, et al.
Publicado: (2016)

The endosomal pH regulator NHE9 is a driver of stemness in glioblastoma
por: Ko, Myungjun, et al.
Publicado: (2022)

Role of Melatonin in Cancer: Effect on Clock Genes
por: Rodríguez-Santana, César, et al.
Publicado: (2023)

ET-06 Suppression of glioblastoma through novel drug based on “Gene Switch Technology”
por: Yamamoto, Etsuko, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_msc3pbetuc3okudu1msf99db2o